Alere and FIND in­tro­duce new di­ag­nos­tic test for sleep­ing sick­ness

BioSpectrum (Asia) - - Company News -

US-based di­ag­nos­tics firm Alere’s sub­sidiary Stan­dard Di­ag­nos­tics in Korea and global non­profit or­gan­i­sa­tion FIND have in­tro­duced a new rapid di­ag­nos­tic test (RDT) for hu­man African try­panoso­mi­a­sis (HAT) or sleep­ing sick­ness.

The new SD BIOLINE HAT 2.0 is an im­munochro­mato­graphic test de­signed to rapidly de­tect an­ti­bod­ies against the sleep­ing sick­ness-caus­ing par­a­site, Try­panosoma bru­cei gam­bi­ense.

The test de­liv­ers re­sults af­ter only 15 min­utes and does not re­quire spe­cialised equip­ment or elec­tric­ity, en­abling us­age even in re­mote and re­source-limited set­tings.

Re­search by the Uni­ver­si­ties of Dundee and Cam­bridge in the UK has con­trib­uted to the devel­op­ment of the test, which is in­tended to aid elim­i­na­tion of the dis­ease in the com­mu­ni­ties of sub-Sa­ha­ran African coun­tries.

The test in­cludes two re­com­bi­nant par­a­site anti­gens that were jointly de­vel­oped by the uni­ver­si­ties. FIND and Stan­dard Di­ag­nos­tics have pre­vi­ously part­nered to de­velop an­other rapid HAT di­ag­nos­tic test, SD BIOLINE HAT, which is cur­rently avail­able in ap­prox­i­mately 17 en­demic coun­tries.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.